Figg, William D., Chau, Cindy H., Price, Douglas K., Till, Cathee, Goodman, Phyllis J., Cho, Yonggon, Varella-Garcia, Marileila, Reichardt, Juergen K.V., Tangen, Catherine M., Leach, Robin J., van Brokhoven, Adrie, Thompson, Ian M., and Lucia, M. Scott (2014) Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial. Urology, 84 (1). pp. 127-131.

PDF (Published Version) - Published Version Restricted to Repository staff only

 

7

5

Abstract

Objective: To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes.

Methods: This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls.

Results: There was no association between the CAG repeat length and the risk of TMPRSS2:ETS–positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS–negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease.

Conclusion: Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.

Actions (Repository Staff Only)

Item Control Page